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Abstract
Background Single-isocenter dynamic conformal arc (SIDCA) therapy is a technically efficient way of delivering stereo-
tactic radiosurgery (SRS) to multiple metastases simultaneously. This study reports on the safety and feasibility of linear
accelerator (LINAC) based SRS with SIDCA for patients with multiple brain metastases.
Methods All patients who received SRS with this technique between November 2017 and June 2019 within a prospective
registry trial were included. The patients were irradiated with a dedicated planning tool for multiple brain metastases using
a LINAC with a 5mm multileaf collimator. Follow-up was performed every 3 months, including clinical and radiological
examination with cranial magnetic resonance imaging (MRI). These early data were analyzed using descriptive statistics
and the Kaplan–Meier method.
Results A total of 65 patients with 254 lesions (range 2–12) were included in this analysis. Median beam-on time
was 23min. The median follow-up at the time of analysis was 13 months (95% CI 11.1–14.9). Median overall survival
and median intracranial progression-free survival was 15 months (95% CI 7.7–22.3) and 7 months (95% CI 3.9–10.0),
respectively. Intracranial and local control after 1 year was 64.6 and 97.5%, respectively. During follow-up, CTCAE grade I
adverse effects (AE) were experienced by 29 patients (44.6%; 18 of them therapy related, 27.7%), CTCAE grade II AEs
by four patients (6.2%; one of them therapy related, 1.5%), and CTCAE grade III by three patients (4.6%; none of them
therapy related). Two lesions (0.8%) in two patients (3.1%) were histopathologically proven to be radiation necrosis.
Conclusion Simultaneous SRS using SIDCA seems to be a feasible and safe treatment for patients with multiple brain
metastases.
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Introduction
Brain metastases (BM) occur in approximately 30% of all
cancer patients [1]. Without treatment, BM are often asso-
ciated with a dismal prognosis and a survival of only about
1 month [2]. Singular or solitary metastases are treated lo-
cally with stereotactic radiosurgery (SRS) or surgical resec-
tion, preferably in combination with adjuvant (stereotactic)
radiotherapy [3–5]. Surgical resection is most often chosen
in case of large and/or symptomatic lesions, because it can
immediately relieve the patient from the burden of space-
occupying effects.
However, almost 80% of all patients with BM have more
than one metastasis [1, 2]. For two to four metastases of lim-
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Table 1 The prescribed dose depending on the tumor’s size




ited size, SRS is the first choice, as this procedure achieves
a fast and effective treatment with high local tumor control
and only rare side effects [6, 7]. For patients with multiple
BMs, whole-brain radiotherapy (WBRT) is the mainstay
of treatment [8]. WBRT is thought to delay neurological
symptoms and prolong intracranial control; however, pa-
tients with poor performance at baseline are unlikely to
benefit [9]. Moreover, WBRT is associated with a spec-
trum of toxicities that often result in irreversible cognitive
decline even within a few months after treatment [10–12].
Through the improvement of systemic therapy with, e.g.,
immunotherapy targeting Programmed cell death protein 1
(PD-1) or Programmed death-ligand 1 (PD-L1), the sur-
vival of patients is steadily improving even in advanced
cancer stages [13]. This also includes patients who have
been treated with WBRT for multiple BMs. As a result, BM
patients are now more frequently affected by a treatment-
associated long-term neurocognitive decline; therefore, cur-
rent approaches are trying to preserve cognitive function
following WBRT [10, 11, 14–20]. The ongoing multicen-
tric HIPPORAD (NOA-14) trial addresses this approach
(results are pending) [16].
A different approach is the use of single-high-dose SRS
for more than four BMs, while sparing the remaining brain
parenchyma [6, 21]. Yamamoto et al. applied SRS to up to
ten BMs in a multicentric prospective non-randomized ob-
servational study and showed that survival and toxicity for
patients with five to ten BMs was non-inferior to patients
with two to four BMs [22]. Even the long-term effects after
a median follow-up of 12.0 months (range 0.3–67.5 months)
were non-inferior [23]. According to further reports by Ya-
mamoto et al., even more than ten BMs may be eligible for
SRS in carefully selected patients [24, 25].
Although Yamamoto et al. have demonstrated non-inferi-
ority, a major problem of SRS of multiple metastases is the
cumulative duration of multiple treatments [26]. When us-
ing conventional multi-isocenter linear accelerator (LINAC)
based SRS, plans get exponentially more complex with each
additional metastasis, as contributions of one lesion’s dose
to the other lesions have to be taken into account. Since
each metastasis is treated with a separate isocenter, addi-
tional time is required for patient setup and verification.
For three BMs, this can easily add up to treatment times of
60min, as each metastasis often requires 20min [27, 28].
Therefore, not only the treatment planning but also the ir-
radiation itself is a time-consuming process.
To solve this problem, specific algorithms have been
developed for Volumetric modulated arc therapy (VMAT)
or dynamic arc therapy, in which a single isocenter is
used while all metastases are simultaneously treated [29,
30]. Another approach to treat multiple metastases si-
multaneously is robotic radiosurgery using, for exam-
ple, CyberKnife® (Accuray Incorporated, Sunnyvale, CA,
USA), which however seems to be a bit more time-con-
suming than LINAC approaches [31]. Brainlab (Munich,
Germany) has developed a specific single-isocenter 4π dy-
namic conformal arc (SIDCA) algorithm and included it in
their Elements Multiple Brain Mets® SRS software. To the
best of our knowledge, the Department of Radiation Oncol-
ogy of the University Hospital, LMU Munich, was the first
center worldwide to use this technique to irradiate multiple
BMs simultaneously using a VersaHD® LINAC (Elekta,
Stockholm, Sweden). Moreover, there are only a few re-
ports of clinical experience with this new technique. In this
study, early results of monocentric prospective data were
evaluated with regard to safety and feasibility of SRS using
SIDCA.
Materials andmethods
Study design and participants
This study was designed as a prospective single-armed reg-
istry trial. In order to be included, a patient was required to
have two or more brain metastases with a diameter of 3 to
25mm each. With a margin of 1mm added to the GTV, the
smallest diameter of the planning target volume (PTV) was
5mm, which corresponds to the isocentric width of one leaf
of the VersaHD® multileaf collimator (Elekta, Stockholm,
Sweden). All tumor entities except lymphoma, germinoma,
or small-cell lung cancer were included. Patients with dis-
seminated cerebral metastases or signs of leptomeningeal
disease were excluded and received other treatments (such
as WBRT) instead. Prior cranial radiotherapy was not an
exclusion criterion; however, the treated metastases were
not allowed to have been directly irradiated with local abla-
tion (simultaneous boost during WBRT or prior SRS). This
study was approved by the ethics committee of the LMU
University Hospital Munich (nr. 573-15). Informed consent
was obtained from all participants.
Planning and prescription
In addition to a contrast-enhanced planning computed to-
mography (CT) scan (with iodine-based contrast agents), all
patients received magnetic resonance imaging (MRI) scans
with gadolinium-based contrast agents, both with a slice
thickness of 1mm. Planning CT and MRI were ideally not
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older than 1 week (maximum 2 weeks old) at the time
of irradiation; usually both were done on the same day to
reduce matching discrepancies. Patients were fixated with
double-layer thermoplastic masks with headSTEP® from
Innovative Technologie Völp (Innsbruck, Austria). Delin-
eation and planning were accomplished using the Elements
Multiple Brain Mets® SRS application by Brainlab (Mu-
nich, Germany). The dose prescription to each metastasis
was dependent on its size and proximity to organs at risk
(mainly optical pathway and brainstem), and was usually
18Gy for metastases of 4.2–15.0cm3 size and 20Gy for
<4.2cm3 (prescribed to the 80% isodose). The prescription
dose depending on the size is listed in Table 1. For large
metastases close to critical structures, 15Gy to the 80% iso-
dose could be prescribed. Additionally, the number of tar-
gets was taken into account during dose prescription. Sahgal
et al. presented a model in which the relative increase of the
V12 value of the brain (brain volume which received 12Gy)
with a higher number of brain metastases was shown; he
therefore recommended “a decrease in the prescription dose
of the order of 1Gy when five or more lesions are treated
with SRS” [32]. Following this recommendation, the pre-
scription dose of each target was usually decreased by 1Gy
once the number of metastases exceeded 5. For the PTV, the
metastasis’ volume was isotropically expanded by a margin
of 1mm. Image guidance was achieved using ExacTrac®
(Brainlab, Munich, Germany) which was connected to the
HexaPOD® system (Elekta, Stockholm, Sweden) [33]. With
this technique a deviation of the patients’ position smaller
than 0.1mm can be achieved.
Prophylactic antiedematous treatment
For irradiation, a prophylactic dexamethasone scheme was
administered which usually consisted of 4–2–0mg on the
day of irradiation, followed by 2–1–0mg, 1–1–0mg, and
1–0–0mg within the first 3 days after treatment. The dosage
was adjusted depending on the size or location of the metas-
tases or the presence of edema and comorbidities (e.g., di-
abetes) requiring appropriate reduction. For prevention of
gastric ulcers, pantoprazole 40mg per day was prescribed
during the days of dexamethasone treatment.
Follow-up
To monitor intracranial local tumor control and the for-
mation of new metastases, contrast-enhanced MRI with
a slice thickness of 1mm was performed every 3 months
after treatment. Whenever new metastases were detected,
further treatment with SRS, WBRT, or surgery was eval-
uated. In case of an increase in the size of the metastases
after irradiation, differentiation between treatment-related
image changes and tumor progression was performed
using fluoroethyl-L-tyrosine positron-emission tomogra-
phy (FET PET) [34]. In case of inconclusive findings of
FET PET, a stereotactic biopsy was performed. In addi-
tion to monitoring intracranial control, the patients were
clinically and neurologically examined during the follow-
up visit. A change in treatment regimens or extracranial
tumor control was recorded as well. The reported AE were
described using the Common Terminology Criteria for
Adverse Events (CTCAE) version 5.0.
Statistics
Statistical analysis was performed using IBM SPSS Statis-
tics version 22 (IBM, Armonk, New York, USA). Descrip-
tive analysis was performed to describe patient and treat-
ment characteristics. Survival analysis was performed using
Kaplan–Meier estimators.
Results
Overall, 65 patients, 35 (53.8%) male and 30 (46.2%) fe-
male, were treated with SIDCA. The first patient under-
went SRS in November 2017 and the last patient in June
2019. The median age at the time of SRS was 61.5 years
(range 22–85 years). With 40 (61.5%) patients, the most fre-
quent entity was non-small-cell lung cancer (NSCLC), in-
cluding 34 adenocarcinomas, 2 squamous cell carcinomas,
and 4 neuroendocrine carcinomas, followed by melanoma
with 10 (15.4%) patients and breast cancer with 7 (10.8%)
patients. 25 (38.5%) patients had no extracranial metas-
tases and 40 (61.5%) patients had extracranial metastases
at the time of treatment. The median Karnofsky perfor-
mance status at the time of radiosurgery was 90% (range
50–100%). The median follow-up at the time of data analy-
sis was 13 months (95% CI: 11.1–14.9 months). 15 (23.7%)
patients had received cranial irradiation before: 6 (9.2%)
WBRT, 1 (1.5%) WBRT with simultaneous boost, 8 prior
SRS (boost and SRS were applied to different lesions than
those treated now). Details of the patient characteristics are
listed in Table 2.
Overall, 254 lesions were treated, of which two (0.8%)
were located in the brainstem. The median number of
treated lesions per patient per therapy session was three
(range 2–12). The median treatment time of the simul-
taneous irradiation of all metastases at once was 23min
(range 12–38min). There was a significant correlation be-
tween number of metastases and treatment time (Pearson
0.516; 95% CI 0.324–0.676; p< 0.001), and total volume
of metastases and treatment time (Pearson: –0.342, 95%
CI –0.570––0.051, p< 0.005) which are depicted in Fig. 1.
The median dose to each metastasis was 19Gy (range
15–20Gy). More information on the dose delivered to the
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Tumor entity of primary tumor







Breast cancer 7 10.8%
Malignant melanoma 10 15.4%
Renal cell cancer 4 6.2%
Colon cancer 1 1.50%
Stomach cancer 1 1.50%
Uterine sarcoma 1 1.50%
Salivary gland carcinoma 1 1.50%
Median follow up time 13 months (95% CI 11.1–14.9)
Therapy following intracranial progression (N= 18)
Second SRS 9 13.8%
Third SRS 1 1.5%
WBRT 8 12.3%
Best supportive care 2 1.5%





































organs at risk and to the irradiated metastases is given in
Tables 3 and 4.
In total, 32 (49.2%) patients experienced AEs. In the
first month after treatment, seven (10.8%) patients experi-
enced acute AEs CTCAE grade 1, such as fatigue, vertigo,
or cephalgia, of which all could be related to the SRS. One
patient (1.5%) who received irradiation of four melanoma
metastases experienced seizures CTCAE grade 2 due to in-
tralesional hemorrhage a week after treatment. Overall, no
acute AEs CTCAE grade 3 were reported. During follow-
up, 28 patients (43.1%) presented AEs: 22 patients (33.8%)
experienced CTCAE grade 1 (11 of them therapy related,
16.9%), four patients (6.2%) experienced CTCAE grade 2
(one of them therapy related, 1.5%), and three patients
(4.6%) CTCAE grade 3 (none of them therapy related).
The AEs are listed in detail in Table 5.
By December 2019, 30 patients (46.2%) had died, five
of them with cerebral progressive disease. Most of the pa-
tients (26.2%) died within the first 3 months after radio-
surgery. Detailed information is given in Fig. 2. Two pa-
tients were lost to follow-up. The median overall survival
(OS) was 15 months (95% CI 7.7–22.3). OS hardly corre-
lated with the calculated GPA score (Pearson 0.186; 95%
CI –0.138–0.488; p= 0.145). There was no significant cor-
relation between number of metastases and overall survival
(Pearson: 0.132; 95% CI –0.114–0.366; p= 0.293). In the
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Fig. 1 Pearson correlation of
treatment time with total volume












































volume of metastases [cm³]
Pearson -0.342; 95%-CI (-0.570) –(-0.051); p<0.005
a
b
follow-up period, 36 patients (55.4%) had neither a ma-
lignant progressive lesion nor new metastases in the brain
after radiosurgery. Local control of the irradiated lesions
after 6 months and 1 year was 97.5%.
A total of 13 lesions (5.1%) of ten patients (16.9%) were
progressive in size after treatment. Three lesions were diag-
nosed with radiation necrosis, one with tumor progression,
and nine were classified clinically and neuroradiologically
as pseudo-progression: these lesions will be highlighted in
this paragraph. One lesion (0.4%) of a triple-negative breast
cancer irradiated with 15Gy had histopathologically veri-
fied tumor progression 6 months after radiosurgery. This pa-
tient additionally had multiple new metastases 1 year after
therapy and was then treated with WBRT (30Gy in 10 frac-
tions). 21 months after SRS and 6 months after WBRT,
the patient developed three new metastases: the pre-irradi-
ated progressive lesion was surgically resected and the rest
were treated with further SRS treatment. Symptomatic radi-
ation necrosis (RN) was diagnosed in three patients (4.6%),
of which two lesions (0.8%) in two patients (3.1%) were
histopathologically verified. One of them was treated with
steroids due to symptoms such as vertigo CTCAE grade 2
with nystagmus, which were almost identical to the ini-
tial symptoms. The other patient experienced vertigo and
K
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Table 3 Dosimetric and volumetric data of the irradiated metastases
Metastases (n= 254) Median Range
Volume GTV (cm3) 0.193 0.010–9.184
Volume PTV (cm3) 0.483 0.060–11.900
Cumulative volume PTV (cm3) 3.373 0.361–12.682
Median dose GTV (Gy) 21.99 16.56–25.04
Median dose PTV (Gy) 20.93 16.19–23.95
PTV prescription (Gy) 19 15–20
GTV gross tumor volume; PTV planning tumor volume
cephalgia CTCAE grade 1 but did not require any antiede-
matous treatment. Another patient developed symptomatic
RN in two metastases, which was clinically and radiologi-
cally diagnosed, but no biopsy was performed. Both lesions
were irradiated with 20Gy. The patient suffered from pare-
sis of the left arm and was first treated with dexamethasone
and then with bevacizumab in analogy to Levin et al. after
insufficient response [35, 36]. Nine lesions (3.5%) in seven
patients (10.8%) were interpreted as pseudo-progression by
an experienced neuroradiologist.
Moreover, 18 patients (27.7%) developed new brain
metastases after their first radiosurgery during the follow-
up period. After the first intracranial progression, eight pa-
tients received WBRT and eight patients received a second
series of SRS. Two patients also received a third radiation
series: one of them was treated with SRS after WBRT and
the other one was treated with a third SRS course. Two
patients are still under active surveillance after showing
only limited progression. The median intracranial progres-
sion-free survival (iPFS) was 7 months (95% CI 3.9–10.0).
The intracranial control rate was 73.0% after 6 months and
64.6% after 12 months.
Table 4 Dosimetric and volumetric data of the organs at risk (OAR)
Organs at risk (N= 65) Median mean dose (Gy) Mean dose range (Gy) Median maximal dose (Gy) Maximal dose range (Gy)
Whole brain 1.38 0.56–2.78 24.34 19.41–27.15
Left hippocampus 1.13 0.26–4.83 1.42 0.30–17.31
Right hippocampus 1.56 0.12–6.03 1.43 0.19–24.92
Brainstem 1.01 0.24–2.28 2.28 0.63–18.15
Optic chiasm 1.08 0.17–4.98 1.37 0.19–8.73
Cochlea left 0.78 0.11–4.99 0.55 0.13–6.75
Cochlea right 0.93 0.08–7.33 0.70 0.08–11.27
Eye left 0.50 0.12–1.85 0.67 0.16–3.66
Eye right 0.53 0.09–2.73 0.77 0.12–8.75
Lens left 0.43 0.11–1.43 0.46 0.13–1.78
Lens right 0.47 0.10–2.28 0.44 0.10–2.71
Optic nerve left 0.80 0.14–4.17 0.88 0.18–6.15
Optic nerve right 0.83 0.12–3.85 0.96 0.14–11.86
Optic tract left 1.18 0.20–4.94 1.17 0.31–11.62
Optic tract right 1.18 0.16–4.91 1.22 0.19–15.71
A total of 38 patients (58.5%) were treated with im-
munotherapy at some point during the course of their
disease. Twelve patients (18.5%) received immunotherapy
within a time period of 4 weeks before and after treat-
ment. Fourteen patients (21.5%) received tyrosine kinase
inhibitors (TKI). Four of these patients (6.2%) were treated
throughout the course of disease, during and after radio-
therapy. Overall, these patients had only few AE, most of
which were unrelated to the cranial irradiation (such as
thyroiditis in one patient, or alopecia in two): two patients
(3.1%) experienced cephalgia CTCAE grade I and two pa-
tients (3.1%) fatigue CTCAE grade I. However, one patient
with malignant melanoma who received nivolumab until
shortly before radiotherapy suffered from a cranial hemor-
rhage in the irradiated metastases a week after radiotherapy
and died a month later. The symptoms included aphasia
CTCAE grade I and seizure CTCAE grade II. No RN was
detected among the patients who received immunother-
apy at the time of radiation. Detailed information about
immunotherapy and small molecule treatment is listed in
Table 2.
Discussion
To date, SRS has mostly been limited to patients with a cer-
tain number of metastases [6, 21]. The question remains
whether there is a limit to how many metastases can be
irradiated using SRS. Hatiboglu et al. suggested that the to-
tal tumor volume has a larger influence on the whole-brain
dose than the number of metastases [37]. In fact, a dosi-
metric analysis by Becker et al. showed that theoretically,
40 metastases of different sizes could be irradiated radiosur-
gically with Gamma Knife® (Elekta, Stockholm, Sweden)
K
Strahlenther Onkol (2021) 197:601–613 607
Table 5 Adverse events experienced by the patients
CTCAE grade I CTCAE grade II CTCAE grade III
Fatigue (number of patients) 26 [40.0%] – –
Fatigue (number of events) Acute 3 [4.6%] – –
After 3 months 10 [15.4%] – –
After 6 months 9 [13.8%] – –
After 9 months 7 [10.8%] – –
After 12 months 6 [9.2%] – –
After 15 months 5 [7.7%] – –
After 18 months 3 [4.6%] – –
Cephalgia (number of patients) 8 [12.3%] 1 [1.5%] –
Cephalgia (number of events) Acute 2 [3.1%] – –
After 3 months 3 [4.6%] – –
After 6 months 4 [6.2%] 1 [1.5%] –
After 9 months 4 [6.2%] – –
After 12 months 1 [1.5%] – –
After 15 months 1 [1.5%] – –
Vertigo (number of patients) 10 [15.4%] – –
Vertigo (number of events) Acute 6 [9.2%] – –
After 6 months 4 [6.2%] – –
After 9 months 2 [3.1%] – –
After 12 months 1 [1.5%] – –
After 15 months 2 [3.1%] – –
After 18 months 1 [1.5%] – –
Motoric impairment (number of patients) 1 [1.5%] – –
Motoric impairment (number of
events)
After 3 months 1 [1.5%] – –
After 9 months 1 [1.5%] – –
Sensitivity disorder (number of patients) 2 [3.1%] – –
Sensitivity disorder (number of
events)
After 6 months 2 [3.1%] – –
After 9 months 1 [1.5%] – –
Aphasia (number of patients) 1 [1.5%] – –
Aphasia (number of events) Acute event 1 [1.5%] – –
After 6 months 1 [1.5%] – –
Neurocognitive impairment (number of patients) 18 [27.7%] – –
Neurocognitive impairment (number
of events)
Acute 2 [3.1%] – –
After 3 months 4 [6.2%] – –
After 6 months 1 [1.5%] – –
After 9 months 8 [12.3%] – –
After 12 months 3 [4.6%] – –
After 15 months 3 [4.6%] – –
Atfer 18 months 2 [3.1%] – –
Seizure (number of patients) 4 [6.2%] – 3 [4.6%]
Seizure (number of events) Acute event – 1 [1.5%] –
After 3 months 1 [1.5%] 1 [1.5%] 2 [3.1%]
After 6 months 1 [1.5%] – –
After 9 months – – 1 [1.5%]
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Table 5 (Continued)
CTCAE grade I CTCAE grade II CTCAE grade III
Alopecia (number of patients) 7 [10.8%] 2 [3.1%] –
Alopecia (number of events) After 3 months 4 [6.2%] 2 [3.1%] –
After 6 months 2 [3.1%] – –
After 9 months 1 [1.5%] – –
After 12 months 1 [1.5%] – –
After 15 months 1 [1.5%] – –
Radiation necrosis (number of symptomatic patients) – – –
Paresis left arm After 1 month 1 [1.5%] – –
Vertigo After 3 months 1 [1.5%] – –
Vertigo, nystagmus After 6 months 1 [1.5%] – –
before a whole-brain dose of 8Gy, corresponding to the
dose of a single fraction of WBRT, had been reached [38,
39]. As mentioned above, Yamamoto et al. were able to
show that SRS of five to ten metastases is non-inferior to
SRS of two to four metastases [22]. Treatment of more than
four metastases might still be a reasonable approach; this
is also recommended as an option in the NCCN guidelines
for viable cases (version 1.2020). However, it is important
to find a suitable radiation technique for this treatment.
This study tested the simultaneous irradiation of multi-
ple metastases using SIDCA on a VersaHD® LINAC from
Elekta (Stockholm, Sweden) by analyzing early results of
a prospective cohort. Other techniques such as VMAT us-
ing HyperArc® (Varian Medical Systems, Palo Alto, Cali-
fornia, USA) have been tested before with good results [30,
40, 41]. From a pure dosimetric point of view, SIDCA was
compared with VMAT in a 2019 study: the SIDCA plans
were reevaluated using Monaco® (Elekta, Stockholm, Swe-
den) as VMAT plans. According to the study, SIDCA can
potentially ensure better protection of healthy brain tissue
and superior treatment efficiency with a steeper dose gradi-
ent if the target volume is nearly spherical, while for non-
spherical volumes VMAT was able to achieve higher con-
formity [42]. The SIDCA plans showed good dose coverage
as they were optimized in such a way that no leaves are open
between two metastases and no sequencing is present. So
even with a leaf width of 5mm, sufficient conformality was
achieved.
In this study 29.2% of the treated patients had five or
more metastases, which matches to MRI observations de-
scribing only about 50%with three or more metastases [43].
The limited number of patients with five or more metastases
can be counted as a limitation of this study, as a larger num-
ber of patients with a higher number of metastases poten-
tially could have more side effects or radiation necrosis and
therefore shorter OS. In the cohort, however, there was no
correlation between OS and the number of treated metas-
tases, but a correlation might still have been seen if more
patients with a larger number of metastases had been in-
cluded. Therefore, this study alone cannot sufficiently show
that SRS is feasible regardless of the number of metastases.
But as other studies, such as Yamamoto et al., have shown
non-inferiority regarding the outcome of patients with five
or more metastases compared to patients with two to four
metastases, the results of this study can be seen as analo-
gous [22, 25]. The main goal of this study is, in the first
place, to show that SRS with SIDCA is feasible and compa-
rable to other techniques. Despite its limitations, the study’s
results showed that SIDCA is a feasible approach for SRS
of multiple metastases.
There is another recent study which evaluated single-
isocenter stereotactic radiosurgery for multiple metastases
with similar good results [45]. However, Palmer et al. used
VMAT instead of dynamic conformal arc therapy, and ap-
plied the dose in 1–5 fractions instead of in a single fraction.
In the latter study, 15-month (95% CI 7.7–22.3) OS was
high compared to other similar studies: Yamamoto et al.
had 10.8 months (05% CI 9.4–12.4) for patients with two
to four and 10.8 months (9.1–12.7) for five to ten metastases
[22]; Limon et al. had 5.8 months (95% CI 4.9–6.6) [44];
Palmer et al. had 13.2 months (95% CI 8.5–18.7 months)
[45]. In a 2019 meta-analysis by Lehrer et al. including
24 trials with patients with single- and multi-fractioned
SRT in definitive and postoperative settings, OS was me-
dian 7.9 months for patients who received single-fraction
definitive SRS [46]. The reason for the better OS in this
study compared to older cohorts is the advance of targeted
therapy such as PD-L1-inhibitors in recent years, which has
improved OS drastically in many settings [47–49]. This was
probably also the reason for little correlation of the OS with
the survival estimated by the GPA score.
As described in the results, the AEs were very lim-
ited, most of them only being CTCAE grade 1. Three pa-
tients experienced seizures CTCAE grade 3: one resulted
from intracranial bleeding after a massive progression, an-
other from leptomeningeal disease, and the last one oc-
curred after receiving WBRT due to disseminated intracra-
nial progress. Furthermore, five patients (7.6%) experienced
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Fig. 2 Kaplan–Meier curves
of intracranial progression-
free survival (iPFS) and overall
survival (OS)
CTCAE grade 2 AEs, one of which was cephalgia due to
posttherapeutic edema, which could be treated with dexam-
ethasone. One patient experienced seizures due to improper
intake of anticonvulsive medication. Another one due to in-
tracranial hemorrhage a week after SRS. The last two pa-
tients had alopecia following systemic treatment. With only
two patients (3.1%) with treatment-related AEs CTCAE
grade 2 and 3 each, the results are comparable to other
literature: Palmer et al. (using VMAT with 1–5 fractions)
only described radionecrosis of the lesions (N= 1014) at
1.4% and 0.9% for grade 2 and grade 3, respectively. Un-
der the assumption that each lesion was in a separate pa-
tient (N= 173), this represented 0.1% and 5.2% for grade 2
and grade 3, respectively. Yamamoto et al. had around 7%
grade 1 and 2 toxicities, 2% grade 3, 1% grade 4, and 1%
grade 5 [22]. Unfortunately, other similar trials did not de-
scribe AEs in enough detail for better comparison, partly
due to short follow-up [40].
Another advantage of the single-isocenter approach is the
time-saving aspect: while multi-isocenter approaches need
K
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approximately 20min per lesion, about the same time is
needed for all lesions simultaneously with SIDCA (in this
study median 23min) [27, 28]. The simultaneous single-
fraction approach also has a great advantage compared to
the hypofractionated approach when combining SRS with
systemic treatments, as SRS can more easily be applied
between cycles.
Concerning RN, the incidence with four lesions (1.6%)
in three patients (4.6%) was lower compared to other lit-
erature. In the meta-analysis by Lehrer et al., the rate of
radiation necrosis was by 18.2% for single-fraction defini-
tive SRS [46]. This can probably be explained by the small
margin of 1mm and the rationally adapted median dose to
the PTVs of 19Gy. Additionally, the limitation of having
a limited number of patients with five or more metastases
might also have played a role in this favorable number.
The prophylactic administration of dexamethasone might
have been a protective factor as well. Altogether, simulta-
neous SRS with SIDCA showed only few side effects in
this prospective monocentric registry trial.
The only metastasis which had histologically verified tu-
mor progression was a triple-negative breast cancer metas-
tasis irradiated with merely 15Gy (prescribed to 80% iso-
dose) due to its size and closeness to the brainstem. Only
two metastases in the cohort were irradiated with 15Gy, of
which one was not locally controlled. This could be an indi-
cation that a single-fraction dose of 15Gy is not sufficient
for local control. Other than that, local control was very
high compared to data of other studies (97.5%): Palmer
et al. had a 1-year local control of 99.0% [45]; Yamamoto
et al. had 93.0% and 93.5% for patients with two to four
and five to ten metastases, respectively [23]; in Lehrer et al.,
local control of the patients who received definitive single-
fraction SRS was at 76.7% after 1 year [46].
Unfortunately, the number of patients receiving parallel
immunotherapy was too low and their follow-up too short
to show any significant additive effect, higher toxicities, or
abscopal effects. This aspect will be highlighted further in
the future.
Conclusion
The simultaneous radiosurgical irradiation of multiple brain
metastases using SIDCA could be applied safely and effi-
ciently in this prospective monocentric registry trial with
good local control and few treatment-related adverse effects
or radiation necroses. Long-term observations for patients
with over four metastases, especially in combination with
systemic treatment, are needed for further validation of this
finding.
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